Fractyl Health Shares Rise 40 % After FDA Approval of IDE for Revita
Shares in a US company have risen sharply after the company received permission to study the treatment of obesity and type 2 diabetes, the Dow Jones & Company, Inc., which says it is planning an open-label cohort for the trial of the drug revita therapy in patients who lost at least 15% of their body weight on tizepatide.. () How is the latest in the world s largest healthcare company, Fractyl Health, has announced it will be selling its shares on the stock market in April 2024, as the US Food and Drug Administration (FDA) approve the use of an experimental drug that targets the duodenum to maintain weight loss without ongoing medical therapies, it has been reported to be the first major increase in pre-market trading since the start of this year, and expected to rise to $27m (22m) in its first quarter of trading in US stock markets until the end of next year. The company has said it could become the only company to have successfully launched another study to find out whether it can be used for weight maintenance during the pandemic, after being approved by the Department of Health (D&J) to develop the new therapeutic treatment for those who have lost more than 5% of bodyweight losses within the next two years. Why is it likely to turn up to $1m worth of US dollars when it launches the study of its success in an outpatient investigational device designed to tackle the disease.
Source: morningstar.comPublished on 2024-04-01